Previous 10 | Next 10 |
Summary Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. When the end to restrictive policy is in sight, then the sector is likely to witness a group rotation to more growth-oriented stocks. Groups like medical d...
Summary As everyone knows, Madrigal outperformed expectations with outstanding results stemming from Maestro NASH study. I assess Madrigal’s current valuation, based on future sales potential of resmetirom in the US as a basis. I arrive at a net present value of $4 billion ma...
Summary Federal Reserve interest rate policy to again remain the market focus this year and create a chaotic first half. Biotechnology should be favorably positioned relative to the market if the economy slips into a recession. Biotech fortunes near term are to be determined by the ...
Madrigal Pharmaceuticals ( NASDAQ: MDGL ) said that an analysis of phase 3 data on resmetirom further reinforces the drug's efficacy at resolving nonalcoholic steatohepatitis ( NASH ) compared to placebo. At 52 weeks of treatment, the consensus read support analysis ...
As previously reported, resmetirom demonstrated improvements in NASH and liver fibrosis on liver biopsies, the primary endpoints of the MAESTRO-NASH trial A supportive analysis using consensus reads of digitized biopsy images by the central pathologists replicated the positive p...
Summary Baker Brothers’ 13F portfolio value decreased from $17.63B to $15.27B this quarter. Rhythm Pharma and Akero Therapeutics were increased while decreasing argenx SE and Horizon Therapeutics. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they a...
Summary Viking Therapeutics has been my top NASH stock for the past few years due to VK2809’s performance, the company’s cash position, and the reasonable valuation. Madrigal Pharmaceuticals reported that their THR β-selective agonist, resmetirom, was able to produc...
Summary TG Therapeutics, Inc. is set to launch Briumvi with an experienced in-house team. There are several factors conducive to launch success. Nevertheless, uncertainty remains. If TG Therapeutics can secure a sales/marketing partnership, the company will likely make a successful ...
Summary Madrigal's lead drug candidate was already expected to be successful in its pivotal trial. FDA approval would then be earned by a positive on one of the trial’s dual endpoints. Because both endpoints were met, something not seen in Phase 3, Madrigal will rule the mark...
You've probably heard of the buy-low-and-sell-high investment strategy, but what about buying high and selling even higher? After sliding throughout most of 2022, shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) jumped nearly 300% higher on Dec. 19, 2022. This is a clinical-stage dru...
News, Short Squeeze, Breakout and More Instantly...
Madrigal Pharmaceuticals Inc. Company Name:
MDGL Stock Symbol:
NASDAQ Market:
Madrigal Pharmaceuticals Inc. Website:
CONSHOHOCKEN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2024 financial results on Wednesday, August 7, 2024, prior to the open of the U.S. financial markets. Following the announcement...
2024-06-30 12:02:00 ET Madrigal Pharmaceuticals (NASDAQ: MDGL) is at a moment of great opportunity, and there's a decent chance that its shareholders will feel good about their investments over the next few years. After commercializing its first medicine, which treats a condition no...
2024-06-16 12:05:00 ET If you're eyeing an investment in Madrigal Pharmaceuticals (NASDAQ: MDGL) , now's the time to imagine a representative of Eli Lilly (NYSE: LLY) interrupting your train of thought by saying something along the lines of, "Not so fast." While the biotech ...